Glimepiride
- Generic Name
- Glimepiride
- Brand Names
- Duetact, Tandemact
- Drug Type
- Small Molecule
- Chemical Formula
- C24H34N4O5S
- CAS Number
- 93479-97-1
- Unique Ingredient Identifier
- 6KY687524K
- Background
First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure a...
- Indication
Glimepiride is indicated for the management of type 2 diabetes in adults as an adjunct to diet and exercise to improve glycemic control as monotherapy.
...
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-12-25
- Lead Sponsor
- Intarcia Therapeutics
- Registration Number
- NCT01455922
- Locations
- 🇺🇸
Intarcia Therapeutics, Inc, Hayward, California, United States
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-12-25
- Lead Sponsor
- Intarcia Therapeutics
- Registration Number
- NCT01455883
- Locations
- 🇺🇸
Intarcia Therapeutics, Inc, Hayward, California, United States
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients
- Conditions
- Interventions
- First Posted Date
- 2011-10-17
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 86
- Registration Number
- NCT01453049
- Locations
- 🇨🇳
GSK Investigational Site, Wuhan, China
Liraglutide and Heart Failure in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2011-08-30
- Last Posted Date
- 2016-09-01
- Lead Sponsor
- Thomas Nystrom
- Target Recruit Count
- 62
- Registration Number
- NCT01425580
- Locations
- 🇸🇪
Karolinska Institutet, Department of Clinical Science and Education, Södersjukhuset, Stockholm, Sweden
🇸🇪Karolinska Institutet, Division of Internal Medicine Södersjukhuset AB, Stockholm, Sweden
A Study in Patients With Type 2 Diabetes
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 240
- Registration Number
- NCT01408095
- Locations
- 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain
Effects of Sitagliptin on Type 2 Diabetes Mellitus Patients on Treatment With Metformin and Insulin
- Conditions
- Interventions
- First Posted Date
- 2011-04-26
- Last Posted Date
- 2014-05-30
- Lead Sponsor
- Jothydev's Diabetes and Research Centre
- Target Recruit Count
- 440
- Registration Number
- NCT01341717
- Locations
- 🇮🇳
Jothydev's Diabetes and Research Center, Thiruvananthapuram, Kerala, India
Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan
- Conditions
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 312
- Registration Number
- NCT01318083
Drug-drug Interaction Study With ASP1941 and Glimepiride
- Conditions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01302158
Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
- Conditions
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 653
- Registration Number
- NCT01296412
Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT01262586
- Locations
- 🇩🇪
Novartis Investigative Site, Mainz, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.